Latest news with #syntheticBiology
Emirates 24/7
3 days ago
- Science
- Emirates 24/7
British scientists develop new genetically modified bacterial strain
British scientists have developed a new strain of Escherichia coli with a genetically recoded genome. According to researchers from the Medical Research Council Laboratory of Molecular Biology, the genetic code is known to consist of triplets of nucleotides, called codons, responsible for synthesising proteins essential for life. In nature, there are 64 codons, although only 21 are required to produce 20 amino acids plus a stop signal. The newly developed strain now contains just 57 codons instead of the usual 64. This development has resulted in the most compact genome among known organisms. By reducing the number of codons, scientists have freed part of the DNA code, creating the potential to design and use novel amino acids not found in nature. In 2019, scientists created the Syn61 strain with 61 codons, which required 18,000 DNA modifications. In the latest study, a team led by synthetic biologist Wesley Robertson carried out more than 100,000 modifications, producing a new strain named Syn57. Robertson noted that Syn57 currently grows four times slower than standard Escherichia coli, but researchers believe further adjustments could improve its growth rate. The earlier Syn61 strain is already used to produce more reliable medicines. Robertson described the new strain as having a radically recoded genome, exemplifying the ability of synthetic biology to transfer genetic sequences into 'realms inaccessible to natural life'. The significance of this engineered bacterium lies in its potential to help create bacteria with unique virus-resistant properties, opening new horizons for the development of innovative medicines and advanced materials. It marks an important step forward in the fields of synthetic biology and genetic engineering. Follow Emirates 24|7 on Google News.
Yahoo
31-05-2025
- Business
- Yahoo
Amyris Buys Ingredion's Stake in the Real Sweet Joint Venture
Amyris and Ingredion Incorporated (NYSE:INGR) have agreed to end their RealSweet joint venture. A close up of a baker stirring a bowl of flour and sugar in a bakery. Amyris will take complete control of the Precision Fermentation Plant in Barra Bonita, Brazil, as part of the new agreement. As a result, Ingredion Incorporated (NYSE:INGR) is granted exclusive access to Amyris' fermented Reb M technology for production and marketing, setting the stage for future collaboration. Both businesses will benefit from improved operational focus and commercial clarity as an outcome of the strategic pivot. Amyris, a synthetic biology pioneer, will fully oversee its Brazilian laboratory, strengthening its vertically integrated approach. Sustainable components used in products all around the world are produced by the company's in-house fermentation platform. Ingredion Incorporated (NYSE:INGR), a worldwide ingredient producer with $7.4 billion in sales in 2024 and operations in more than 120 countries, will use its exclusive rights to fermented Reb M, a sugar substitute. Through this collaboration, Amyris fortifies its core production capabilities for future expansion, while Ingredion expands its portfolio of functional sweeteners. While we acknowledge the potential of INGR to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than INGR and that has 100x upside potential, check out our report about this READ NEXT: and . Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
